Treatment Related Cancer
7
1
2
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
Socioeconomic Inequalities in the Diagnosis and Treatment of Colon and Ovarian Cancer in England Between 2016-2017
A Multicenter Trial of PLA vs. Surgery for Treating PTMC
Pancreatic Cyst Ablation With a Monopolar Radiofrequency Ablation Probe
Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
A Coordination Card of Care Relative to the Medicinal Treatments Got Out of it From Hospitalization